Every material Form 8-K ProMIS Neurosciences Inc. has filed with the SEC since May 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ProMIS Neurosciences reported a net loss of $11.7 million, or $1.28 per share, for the quarter ended June 30, 2026, up from a $10.1 million loss a year earlier. Cash and short-term investments were $53.4 million, which the company says will fund operations through 2027, past the expected first quarter 2027 topline readout from its PRECISE-AD trial. Per-share loss narrowed mainly because of more weighted-average shares after a January 2026 financing.
Q2 2026 net loss was $11.7 million ($1.28 per share), versus $10.1 million ($7.26 per share) in Q2 2025
Cash and short-term investments were $53.4 million at June 30, 2026, up from $6.1 million at December 31, 2025
The increase reflects $70.1 million in net proceeds from a January 2026 private placement, in which certain directors and management participated
Unblinded 12-month PRECISE-AD topline data is expected in the first quarter of 2027
ProMIS Neurosciences reported blinded six-month interim safety and biomarker data for PMN310 in its Phase 1b PRECISE-AD trial in early Alzheimer's disease, with no ARIA-E cases reported across 136 safety-evaluable patients. The trial remains blinded and ongoing, and the company said unblinded 12-month topline results, including efficacy data, are expected in the first quarter of 2027. The filing contains no financial results, so the update is clinical data that shareholders will weigh ahead of the readout.
No ARIA-E reported as of the July 22, 2026 data cutoff; 4.4% total ARIA, all mild and asymptomatic (ARIA-H only)
68.5% of patients had a plasma pTau217 decline from baseline and 62.5% had a CSF MTBR-tau243 decline; the company says allocations are still blinded
Unblinded 12-month topline results expected in Q1 2027, including efficacy data
Webinar held July 28, 2026 at 8:00 a.m. E.T. with KOLs Dr. Will Mantyh and Dr. Michael Weiner
At its 2026 Annual Meeting on May 20, 2026, ProMIS Neurosciences shareholders approved an amendment adding 900,000 Common Shares to the 2025 Stock Option and Incentive Plan. Shareholders also elected all seven director nominees and ratified Baker Tilly US, LLP as the independent registered public accounting firm for fiscal 2026.
Plan amendment approved with 3,352,388 votes for, 774,193 against, 20,800 abstentions and 614,643 broker non-votes.
All seven nominees elected, including Neil Cashman, M.D. with 4,143,889 votes for and Eugene Williams with 4,108,919.
Baker Tilly US, LLP ratified with 4,657,634 votes for, 4,415 against and 99,975 abstentions.
Holders of 4,762,024 Common Shares, about 53.1% of 8,967,693 outstanding, were present or represented by proxy.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ProMIS Neurosciences Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →